Gallic acid-based indanone derivatives as anticancer agents

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 14, 2008, Pages 3914-3918

  Saxena, Hari Om ^a   Faridi, Uzma ^b   Srivastava, Suchita ^b   Kumar, J K ^b   Darokar, M P ^b   Luqman, Suaib ^b   Chanotiya, C S ^b   Krishna, Vinay ^b   Negi, Arvind S ^b   Khanuja, S P S ^b  

^a Rain Forest Research Institute   (India)

^b CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

Author keywords

Anticancer; Gallic acid; HMQC; Indanones; Osmotic fragility

Indexed keywords

3 (3',4',5' TRIMETHOXYPHENYL) 4,5,6 TRIMETHOXYINDAN 1 ONE; ANTINEOPLASTIC AGENT; GALLIC ACID; INDANONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN MCF 7; DRUG SYNTHESIS; ERYTHROCYTE FRAGILITY; HEMOLYSIS; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ERYTHROCYTES; GALLIC ACID; HEMOLYSIS; HUMANS; INDANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; OSMOSIS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 47349103796     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.06.039     Document Type: Article

References (38)

1. CIMAP Communication No. 2008-80J.
2. Schumann H., Stenzel O., and Girgsdies F. Organometallics 20 (2001) 1743
3. Herzog M.N., Chien J.C.W., and Rausch M.D. J. Organomet. Chem. 654 (2002) 29
4. Sato, Y. Jpn. Kokai Tokkyo Koho 1998, 10298126.
5. Sato Y. Chem. Abstr. 130 (1999) 13852
6. Leoni L.M., Hamel E., Genini D., Shih H., Carrera C.J., Cottam H.B., and Carson D.A. J. Natl. Cancer Inst. 92 (2000) 217
7. Sugimoto H. Pure Appl. Chem. 71 (1999) 2031
8. Beukes D.R., Davies-Coleman M.T., Kelly-Borges M., Harper M.K., and Faulkner D.J. J. Nat. Prod. 61 (1998) 699
9. Pellissier H. Tetrahedron 61 (2005) 6479
10. Frontier A., and Collinson C. Tetrahedron 61 (2005) 7577
11. Coyanis E.M., Panayides J.L., Fernandes M.A., de Koning C.B., and van Ottoerlo W.A.L. J. Organomet. Chem. 691 (2006) 5222
12. Clark W.M., Tickner-Eldridge A.M., Huang G.K., Pridgen L.N., Olsen M.A., Mills R.J., Lantos I., and Baine N.H. J. Am. Chem. Soc. 120 (1998) 4550
13. Wang G., Zheng C., and Zhao G. Tetrahedron: Asymmetry 17 (2006) 2074
14. Kajiro H., Mitamura S., Mori A., and Hiyama T. Tetrahedron: Asymmetry 9 (1998) 907
15. Torisawa Y., Aki S., and Minamikawa J. Bioorg. Med. Chem. Lett. 17 (2007) 453
16. Cui D.M., Zhang C., Kawamura M., and Shimada S. Tetrahedron Lett. 45 (2004) 1741
17. Yadav J.S., Reddy G.S.K.K., Sabitha G., Krishna A.D., Prasad A.R., Rahaman H.R.R., Rao K.V., and Rao A.B. Tetrahedron: Asymmetry 18 (2007) 717
18. Sharma A.K., Subramani A.V., and Gorman C.B. Tetrahedron 63 (2007) 389 and Refs. 2-9 cited in the paper
19. Negi A.S., Darokar M.P., Chattopadhyay S.K., Garg A., Bhattacharya A.K., Srivastava V., and Khanuja S.P.S. Bioorg. Med. Chem. Lett. 15 (2005) 1243
20. Negi A.S., Chattopadhyay S.K., Srivastava S., and Bhattacharya A.K. Synth. Commun. 35 (2005) 15
21. Srivastava V., Negi A.S., Kumar J.K., Faridi U., Sisodia B.S., Darokar M.P., Luqman S., and Khanuja S.P.S. Bioorg. Med. Chem. Lett. 16 (2006) 911
22. Srivastava V., Saxena H.O., Shanker K., Kumar J.K., Luqman S., Gupta M.M., Khanuja S.P.S., and Negi A.S. Bioorg. Med. Chem. Lett. 16 (2006) 4603
23. Srivastava V., Darokar M.P., Fatima A., Kumar J.K., Chowdhury C., Dwivedy G.R., Shrivastava K., Gupta V., Chattopadhyay S.K., Luqman S., Saxena H.O., Gupta M.M., Negi A.S., and Khanuja S.P.S. Bioorg. Med. Chem. 13 (2007) 518
24. Srivastava V., Negi A.S., Kumar J.K., Gupta M.M., and Khanuja S.P.S. Bioorg. Med. Chem. 13 (2005) 5892
25. Furniss B.S., Hannaford A.J., Smith P.W.G., and Tatchel A.R. Book, Vogel's Text Book of practical organic chemistry (1998), Addison-Wesley Longman, Inc., Reading, MA 1034
26. Lawrence N.J., Armitage E.S.M., Greedy B., Cook D., Ducki S., and McGown A.T. Tetrahedron Lett. 47 (2006) 1637
27. Saxena H.O., Faridi U., Kumar J.K., Luqman S., Daroker M.P., Shanker K., Chanotiya C.S., Gupta M.M., and Negi A.S. Steroids 72 (2007) 892
28. Syntheses: General procedure for preparing indanone derivatives from chalcones: Synthesis of 3-(3′,4′,5′-Trimethoxyphenyl)-4,5,6-trimethoxy-indan-1 -one (10). In a Borosil test tube, chalcone 9 (150 mg, 0.39 mmol) was taken in trifluoroacetic acid (0.5 ml) and the tube was sealed carefully with flame. The reaction mixture was heated at 120 °C for 4 h. The reaction mixture was poured into crushed ice and extracted with ethyl acetate, organic layer was washed with water, dried over anhydrous sodium sulphate and evaporated in vacuo. The crude residue thus obtained was purified through column chromatography on silica gel using ethyl acetate-hexane as eluent. The desired indanone 10 was obtained as a solid. It was recrystallised with chloroform-hexane (1:3) to get 10 as a light brown solid.
29. Synthesis of 3-(3′,4′,5′-Trimethoxyphenyl)-4,5,6-trimethoxy-indan (20). Indanone 10 (100 mg, 0.26 mmol) was taken in trifluoroacetic acid (2.5 ml) and the reaction flask was stirred in an ice-bath. After stirring for 5 min sodium borohydride (100 mg, 2.6 mmol) was added in portions with maintaining the bath temperature 0-15 °C for an hour. After that the reaction mixture was stirred at room temperature for 6 h. On completion, 10 ml water was added to reaction mixture and it was extracted with ethyl acetate, organic layer was washed with water, dried over anhydrous sodium sulphate and evaporated in vacuo. The crude residue thus obtained was purified through column chromatography on silica gel using ethyl acetate-hexane as eluent. The desired indan 20 was obtained as oil.
30. 2-Hydroxy, 3-(3′,4′,5′-trimethoxyphenyl)-4,5,6-trimethoxy-ind-2-e n-1-one (16). Indanone 10 (100 mg, 0.26 mmol) was taken in a round-bottomed flask with 1,4-dioxane (10 ml) and selenium dioxide (290 mg, 2.6 mmol). The reaction mixture was refluxed for 6 h. On completion, reaction mixture was filtered and filtrate was evaporated in vacuo. The crude mass thus obtained was purified through column chromatography on silica gel using ethyl acetate-hexane as eluent. The cyclised product 17 was first obtained followed by the desired derivative 16.
31. 2 incubator at 37 °C. The concentration of DMSO were always kept below 1.25%, which was found to be non-toxic to cells. Then, 10 μL MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was added to each well and plates were incubated at 37 °C for 4 h. DMSO (100 μL) was added to all wells and mixed thoroughly to dissolve the dark blue crystals. The plates were read on SpectraMax 190 Microplate reader (Molecular Devices Inc. USA) at 570 nm within 1 h of DMSO addition.
32. 50 (mean erythrocyte fragility) value, which is the saline concentration at which 50% of the cells haemolyse at standard pH and temperature, was then obtained from the curve.
33. Woerdenbag H.J., Moskal T.A., Pras N., Malingré T.M., Farouk S., EI-Feraly H., Kampinga H., and Konings A.W.T. J. Nat. Prod. 56 (1993) 849
34. +], 372, 357.
35. Luqman S., and Rizvi S.I. Asia Pacific J. Pharmacol. 16 (2004) 53
36. Luqman S., Obli Prabu K.V., Pal A., Saikia D., Darokar M.P., and Khanuja S.P.S. Nat. Prod. Commun. 1 (2006) 481
37. Luqman S., Kumar N., and Rizvi S.I. University Allahabad Studies 3 (2004) 29
38. Dacie, J. V.; Lewis, S. M. Practical Hematology, 1984; Orient Longman, p 152.